Literature DB >> 25567416

Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy.

Peter Vestergaard1.   

Abstract

BACKGROUND: Bone health may be impaired in children with epilepsy.
OBJECTIVES: Our objective was to characterize bone mineral density (BMD) and bone growth in children receiving antiepileptic drugs (AEDs) and to assess the effects of co-morbidity, vitamin D deficiency, and type of drugs used. DATA SOURCES: Data were sourced from PubMed, Embase, and Web of Science. ELIGIBILITY CRITERIA: Cross-sectional, cohort, case-control, or randomized controlled trials reporting BMD or parameters of bone growth. PARTICIPANTS: Children with epilepsy compared with controls.
INTERVENTIONS: AEDS or ketogenic diet. STUDY APPRAISAL: The studies were evaluated by one author. SYNTHESIS
METHODS: Studies were categorized as reporting reduced BMD or not at any skeletal site as outcome. A logistic regression was performed for age, percent boys, study design, type of AED, co-morbidity or not, and signs of vitamin D deficiency/osteomalacia or not.
RESULTS: Carbamazepine and valproate were analyzed as monotherapy in 11 studies, and for both drugs a limited decrease in BMD seemed present. For oxcarbazepine, levetiracetam, phenytoin, phenobarbital, and topiramate, only one study with monotherapy was found for each drug, none of which reported decreased bone density. Polytherapy with AEDs seemed to be associated with a larger decrease in bone density than was monotherapy. Although few studies were available on bone growth, these did indicate that bone growth may be impaired among users of AEDs. Ketogenic diet may be associated with decreased bone density. The main determinant of normal BMD was absence of vitamin D deficiency/osteomalacia. LIMITATIONS: The studies differed in skeletal sites studied and most were cross-sectional. No head-to-head comparisons of AEDs were performed. Children treated with polytherapy or ketogenic diet may have more complicated and severe disease than those treated with monotherapy. The underlying cause of epilepsy and vitamin D deficiency may contribute to impaired bone growth and density.
CONCLUSIONS: Reduced bone density, impaired bone growth, and vitamin D deficiency may be seen in children treated with drugs against epilepsy. IMPLICATIONS: Measures to correct vitamin D deficiency, calcium intake should be taken.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25567416     DOI: 10.1007/s40272-014-0115-z

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  66 in total

1.  The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy.

Authors:  Ayse Aksoy; F Müjgan Sönmez; Orhan Deger; Ilgin Hosver; Gülay Karagüzel
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.

Authors:  I Lambrinoudaki; G Kaparos; E Armeni; A Alexandrou; C Damaskos; E Logothetis; M Creatsa; A Antoniou; E Kouskouni; N Triantafyllou
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

3.  Effect of vitamin D on bone mineral mass in normal subjects and in epileptic patients on anticonvulsants: a controlled therapeutic trial.

Authors:  C Christiansen; P Rodbro; M Lund
Journal:  Br Med J       Date:  1973-04-28

4.  Initial and maintenance dose of vitamin D2 in the treatment of anticonvulsant osteomalacia.

Authors:  C Christiansen; P Rodbro
Journal:  Acta Neurol Scand       Date:  1974       Impact factor: 3.209

5.  Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years.

Authors:  G Kafali; T Erselcan; F Tanzer
Journal:  Clin Pediatr (Phila)       Date:  1999-02       Impact factor: 1.168

6.  The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.

Authors:  Kanitpong Phabphal; Alan Geater; Kitti Limapichart; Pornchai Sathirapanya; Suwanna Setthawatcharawanich; Natthawan Witeerungrot; Natawan Thammakumpee; Ratana Leelawattana
Journal:  Epilepsia       Date:  2013-01-02       Impact factor: 5.864

Review 7.  The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Charlotte Beaudart; Fanny Buckinx; Véronique Rabenda; Sophie Gillain; Etienne Cavalier; Justine Slomian; Jean Petermans; Jean-Yves Reginster; Olivier Bruyère
Journal:  J Clin Endocrinol Metab       Date:  2014-07-17       Impact factor: 5.958

8.  [Nutritional status and bone mineral mass in children treated with ketogenic diet].

Authors:  Simona Bertoli; Licia Striuli; Giulio Testolin; Simonetta Cardinali; Pierangelo Veggiotti; Gian Carlo Salvatori; Anna Tagliabue
Journal:  Recenti Prog Med       Date:  2002-12

9.  Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy.

Authors:  I-Jun Chou; Kuang-Lin Lin; Huei-Shyong Wang; Chao-Jan Wang
Journal:  Acta Paediatr Taiwan       Date:  2007 Nov-Dec

10.  Evaluation of bone mineral density in children receiving antiepileptic drugs.

Authors:  R Akin; V Okutan; U Sarici; A Altunbas; E Gökçay
Journal:  Pediatr Neurol       Date:  1998-08       Impact factor: 3.372

View more
  7 in total

Review 1.  The Impact of Psychotropic Medications on Bone Health in Youth.

Authors:  Jessie N Rice; Carrie B Gillett; Nasuh M Malas
Journal:  Curr Psychiatry Rep       Date:  2018-09-24       Impact factor: 5.285

2.  Blood DNA methylation pattern is altered in mesial temporal lobe epilepsy.

Authors:  Hong-Yu Long; Li Feng; Jin Kang; Zhao-Hui Luo; Wen-Biao Xiao; Li-Li Long; Xiao-Xin Yan; Luo Zhou; Bo Xiao
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

3.  Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.

Authors:  Eric H Kossoff; Beth A Zupec-Kania; Stéphane Auvin; Karen R Ballaban-Gil; A G Christina Bergqvist; Robyn Blackford; Jeffrey R Buchhalter; Roberto H Caraballo; J Helen Cross; Maria G Dahlin; Elizabeth J Donner; Orkide Guzel; Rana S Jehle; Joerg Klepper; Hoon-Chul Kang; Danielle A Lambrechts; Y M Christiana Liu; Janak K Nathan; Douglas R Nordli; Heidi H Pfeifer; Jong M Rho; Ingrid E Scheffer; Suvasini Sharma; Carl E Stafstrom; Elizabeth A Thiele; Zahava Turner; Maria M Vaccarezza; Elles J T M van der Louw; Pierangelo Veggiotti; James W Wheless; Elaine C Wirrell
Journal:  Epilepsia Open       Date:  2018-05-21

4.  Bone Health in Rats With Temporal Lobe Epilepsy in the Absence of Anti-Epileptic Drugs.

Authors:  Rhys D Brady; Ker Rui Wong; Dale L Robinson; Richelle Mychasiuk; Stuart J McDonald; Ryan A D'Cunha; Glenn R Yamakawa; Mujun Sun; John D Wark; Peter Vee Sin Lee; Terence J O'Brien; Pablo M Casillas-Espinosa; Sandy R Shultz
Journal:  Front Pharmacol       Date:  2019-10-29       Impact factor: 5.810

5.  Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies.

Authors:  Li Min; Wang Chunyan; Rong Biaoxue
Journal:  BMC Pediatr       Date:  2020-03-02       Impact factor: 2.125

6.  Anticonvulsant use and fracture: a case-control study.

Authors:  Vinoomika Chandrasekaran; Amanda L Stuart; Julie A Pasco; Sharon L Brennan-Olsen; Michael Berk; Jason M Hodge; Rasika M Samarasinghe; Lana J Williams
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-09-01       Impact factor: 2.041

7.  Greater Calcium Intake is Associated with Better Bone Health Measured by Quantitative Ultrasound of the Phalanges in Pediatric Patients Treated with Anticonvulsant Drugs.

Authors:  Vicente Vera; Jose M Moran; Patricia Barros; Maria L Canal-Macias; Rafael Guerrero-Bonmatty; Carmen Costa-Fernandez; Jesus M Lavado-Garcia; Raul Roncero-Martin; Juan D Pedrera-Zamorano
Journal:  Nutrients       Date:  2015-12-01       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.